Shokoofe H Noori

List of Publications by Year
in descending order

22 papers	393 citations	840776 11 h-index	752698 20 g-index
22 all docs	22 docs citations	22 times ranked	647 citing authors

#	Article	IF	Citations
1	Anticancer properties of novel zinc oxide quantum dot nanoparticles against breast cancer stem-like cells. Anti-Cancer Drugs, 2022, 33, e311-e326.	1.4	3
2	Naringenin enhances anti-proliferation effect of 1-ferrocenyl-3-(4-methylsulfonylphenyl) propen-1-one on two different cells via targeting calmodulin signaling pathway. Molecular Biology Reports, 2022, 49, 1027-1036.	2.3	1
3	Naringenin and cryptotanshinone shiftÂthe immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer. BMC Complementary Medicine and Therapies, 2022, 22, .	2.7	6
4	Anti-Breast Cancer Activities of Ketoprofen-RGD Conjugate by Targeting Breast Cancer Stem-Like Cells and Parental Cells. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 1027-1036.	1.7	7
5	Vitamin D Receptor Gene Polymorphisms and the Risk of Metabolic Syndrome (MetS): A Meta-Analysis. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 943-955.	1.2	5
6	Anti-Breast Cancer Activities of 8-Hydroxydaidzein by Targeting Breast Cancer Stem-Like Cells. Journal of Pharmacy and Pharmaceutical Sciences, 2020, 23, 47-57.	2.1	9
7	The Effect of a Newly Synthesized Ferrocene Derivative against MCF-7 Breast Cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/STAT3 Signaling Pathway. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 875-886.	1.7	10
8	A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 2285-2292.	1.7	7
9	Naringenin Enhances the Anti-Cancer Effect of Cyclophosphamide against MDA-MB-231 Breast Cancer Cells Via Targeting the STAT3 Signaling Pathway. Iranian Journal of Pharmaceutical Research, 2020, 19, 122-133.	0.5	16
10	STAT3-mediated Apoptotic-enhancing Function of Sclareol Against Breast Cancer Cells and Cell Sensitization to Cyclophosphamide. Iranian Journal of Pharmaceutical Research, 2020, 19, 398-412.	0.5	2
11	Tehranolide inhibits cell proliferation via calmodulin inhibition, PDE, and PKA activation. Tumor Biology, 2014, 35, 257-264.	1.8	17
12	Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line. Chinese Journal of Integrative Medicine, 2014, 20, 618-623.	1.6	21
13	Cloning, Expression, Purification and Toxicity Evaluation of Helicobacter pylori Outer Inflammatory Protein A. Indian Journal of Microbiology, 2013, 53, 391-394.	2.7	6
14	Antitumor and immunomodulatory effects of salvigenin on tumor bearing mice. Cellular Immunology, 2013, 286, 16-21.	3.0	20
15	Tehranolide inhibits proliferation of MCF-7 human breast cancer cells by inducing G0/G1 arrest and apoptosis. Free Radical Biology and Medicine, 2012, 52, 1987-1999.	2.9	42
16	Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. International Immunopharmacology, 2011, 11, 1802-1808.	3.8	51
17	Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. Cellular Immunology, 2011, 271, 67-72.	3.0	49
18	Multiwalled carbon nanotubes effect on the bioavailability of artemisinin and its cytotoxity to cancerous cells. Journal of Nanoparticle Research, 2011, 13, 6339-6346.	1.9	8

#	Article	IF	Citations
19	Sclareol modulates the Treg intra-tumoral infiltrated cell and inhibits tumor growth in vivo. Cellular Immunology, 2010, 263, 148-153.	3.0	34
20	Tehranolide molecule modulates the immune response, reduce regulatory T cell and inhibits tumor growth in vivo. Molecular Immunology, 2010, 47, 1579-1584.	2.2	22
21	Dihydroartemisinin can inhibit calmodulin, calmodulin-dependent phosphodiesterase activity and stimulate cellular immune responses. International Immunopharmacology, 2010, 10, 213-217.	3.8	16
22	A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. International Immunopharmacology, 2010, 10, 1055-1061.	3.8	41